Posted by Michael Wonder on 07 Sep 2017
Enzyvant receives FDA rare paediatric disease designation for investigational therapy RVT-802
5 September 2017 - RVT-802 has also received breakthrough therapy designation, regenerative medicine advanced therapy designation, and orphan drug designation from FDA.
Enzyvant today announced that the U.S. FDA has granted rare paediatric disease designation to RVT-802, Enzyvant's investigational tissue-based therapy for the treatment of primary immune deficiency resulting from congenital athymia associated with complete DiGeorge Syndrome.
